Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: AGS-003 plus standard treatment in advanced renal cell carcinoma
2012-000871-17Phase 3Terminated
- Sponsor
- Argos Therapeutics
- Start
- Feb 2013
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rocapuldencel-T in renal cell carcinoma (RCC) (2 arms), sponsored by Argos Therapeutics. Primary endpoint: Overall survival. Started Feb 2013; status: terminated.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2012-000871-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000871-17.